Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Heparinoid 0.3% cream
1314000H0AAAAAA
|
Heparinoid (Topical circulatory preparations) | Heparinoid | Skin | 11,430 |
|
Cetomacrogol cream (Formula A)
1301010D0AAAAAA
|
Cetomacrogol | Cetomacrogol | Skin | 11,362 |
|
Elidel 1% cream
1305030B0BBAAAA
|
Elidel | Pimecrolimus | Skin | 11,306 |
|
Clindamycin 1% / Tretinoin 0.025% gel
1306010ABAAAAAA
|
Clindamycin/tretinoin | Clindamycin/tretinoin | Skin | 11,137 |
|
Exorex lotion
1305020C0BRAACX
|
Exorex | Tars | Skin | 10,915 |
|
Cocois ointment
1305020V0BBAAAA
|
Cocois | Cocois | Skin | 10,833 |
|
Dalacin T 1% topical lotion
1306010F0BBABAB
|
Dalacin T | Clindamycin phosphate | Skin | 10,803 |
|
Urea 10% cream
1302010U0AAAFAF
|
Urea (Emollient) | Urea | Skin | 10,713 |
|
Elocon 0.1% cream
1304000Y0BBAAAA
|
Elocon | Mometasone furoate | Skin | 10,365 |
|
Epiduo 0.3%/2.5% gel
1306010Z0BBABAB
|
Epiduo | Adapalene and benzoyl peroxide | Skin | 10,330 |
|
Fucidin 20mg/g cream
1310012F0BBAAAB
|
Fucidin (Topical Cream/Gel) | Fusidic acid | Skin | 10,075 |
|
Oilatum shower gel fragrance free
1302011L0BKACAH
|
Oilatum | Light liquid paraffin | Skin | 9,919 |
|
Oilatum Bath Formula
1302011L0BKADAI
|
Oilatum | Light liquid paraffin | Skin | 9,885 |
|
Daktarin 2% cream
1310020N0BBAAAA
|
Daktarin (Miconazole nitrate) | Miconazole nitrate | Skin | 9,873 |
|
Doublebase emollient shower gel
130201000BBMFCA
|
Proprietary compound emollients | Other emollient preparations | Skin | 9,811 |
|
Zineryt lotion
1306010I0BCAAAB
|
Zineryt | Erythromycin | Skin | 9,764 |
|
Co-cyprindiol 2000microgram/35microgram tablets
1306020C0AAAAAA
|
Co-cyprindiol | Co-cyprindiol (Cyprote acetate/ethinylestradiol) | Skin | 9,657 |
|
Metanium Nappy Rash ointment
130202000BBADAZ
|
Proprietary compound preparation BNF 1302020 | Other barrier preparations | Skin | 9,611 |
|
Betamethasone dipropionate 0.05% / Salicylic acid 3% oint
1304000D0AABBBB
|
Betamethasone esters | Betamethasone esters | Skin | 9,168 |
|
Menthol 2% in Aqueous cream
1303000AAAAACAC
|
Menthol (Topical) | Menthol | Skin | 8,944 |
|
Treclin 1%/0.025% gel
1306010ABBBAAAA
|
Treclin | Clindamycin/tretinoin | Skin | 8,809 |
|
Protopic 0.03% ointment
1305030C0BBABAC
|
Protopic | Tacrolimus | Skin | 8,773 |
|
Clindamycin 1% gel
1306010F0AAADAD
|
Clindamycin phosphate (Topical) | Clindamycin phosphate | Skin | 8,735 |
|
Malathion 0.5% aqueous liquid
1310040M0AAADAD
|
Malathion | Malathion | Skin | 8,496 |
|
Betamethasone diprop 0.05%/Salicylic acid 2% scalp applic
1304000D0AABDBD
|
Betamethasone esters | Betamethasone esters | Skin | 8,449 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.